2 unknown. 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Unknown 2 |
Follow Curegenix Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase 1 Dose Escalation Study of CGX1321 in Subjects With Advanced Gastrointestinal Tumors CGX1321 - Colorectal Adenocarcinoma, Gastric Adenocarcinoma | Phase 1 | Unknown | Curegenix Inc. | 39 | 2017-06-17 | 2020-07-24 |
| CGX1321 in Subjects With Advanced Solid Tumors and CGX1321 With Pembrolizumab or Encorafenib + Cetuximab in Subjects With Advanced GI Tumors (Keynote 596) CGX1321, Pembrolizumab, encorafenib - Solid Tumors, GI Cancer | Phase 1 | Unknown | Curegenix Inc. | 72 | 2016-02-01 | 2022-01-26 |
Gastrointestinal Neoplasms (2) · Bile Duct Neoplasms (1) · Carcinoma, Hepatocellular (1) · Esophageal Neoplasms (1)
CGX1321 (2) · Cetuximab (1) · encorafenib (1) · pembrolizumab (1)
China (1) · Taiwan (1) · United States (1)